دورية أكاديمية
Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort study
| العنوان: | Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort study |
|---|---|
| المؤلفون: | McLean, LS, Lim, AM, Bressel, M, Lee, J, Ladwa, R, Guminski, AD, Hughes, B, Bowyer, S, Briscoe, K, Harris, S, Kukard, C, Zielinski, R, Alamgeer, M, Carlino, M, Mo, J, Park, JJ, Khattak, MA, Day, F, Rischin, D |
| بيانات النشر: | WILEY |
| سنة النشر: | 2024 |
| المجموعة: | The University of Melbourne: Digital Repository |
| الوصف: | OBJECTIVES: To review the outcomes of immune checkpoint inhibitor (ICI) treatment of advanced cutaneous squamous cell carcinoma (CSCC) outside clinical trials. STUDY DESIGN: Retrospective observational study; review of patient records in fifteen Australian institutions. SETTING, PARTICIPANTS: All Australian adults with locally advanced or metastatic CSCC not amenable to curative surgery or radiotherapy treated with ICIs, 5 May 2017 - 23 May 2022, through a cemiplimab compassionate access scheme (Therapeutic Goods Administration Special Access Scheme) or who personally covered the cost of pembrolizumab prior to the start of the access scheme. MAIN OUTCOME MEASURES: Best overall response rate (ORR) according to standardised assessment criteria using the hierarchy: Response Evaluation Criteria in Solid Tumors (RECIST 1.1), the modified World Health Organization clinical response criteria, and the Positron Emission Tomography Response Criteria (PERCIST 1.0); overall and progression-free survival. RESULTS: A total of 286 people with advanced CSCC received ICI therapy during May 2017 - May 2022 (cemiplimab, 270; pembrolizumab, 16). Their median age was 75.2 years (range, 39.3-97.5 years) and 232 were men (81%); median follow-up time was 12.2 months (interquartile range, 5.5-20.5 months). Eighty-eight people (31%) were immunocompromised, 27 had autoimmune disease, and 59 of 277 (21%) had ECOG performance scores of 2 or 3. The ORR was 60% (166 of 278 evaluable patients): complete responses were recorded for 74 (27%) and partial responses for 92 patients (33%). Twelve-month overall survival was 78% (95% confidence interval [CI], 72-83%); progression-free survival was 65% (95% CI, 58-70%). Poorer ECOG performance status was associated with poorer overall survival (per unit: adjusted hazard ratio [aHR], 3.0; 95% CI, 2.0-4.3) and progression-free survival (aHR, 2.4; 95% CI, 1.8-3.3), as was being immunocompromised (overall: aHR, 1.8; 95% CI, 1.1-3.0; progression-free: aHR, 1.8; 95% CI, 1.2-2.7). Fifty-five people (19%) ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 0025-729X 1326-5377 |
| العلاقة: | NHMRC/1175929; McLean, L. S., Lim, A. M., Bressel, M., Lee, J., Ladwa, R., Guminski, A. D., Hughes, B., Bowyer, S., Briscoe, K., Harris, S., Kukard, C., Zielinski, R., Alamgeer, M., Carlino, M., Mo, J., Park, J. J., Khattak, M. A., Day, F. & Rischin, D. (2024). Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort study. MEDICAL JOURNAL OF AUSTRALIA, 220 (2), pp.80-90. https://doi.org/10.5694/mja2.52199Test.; http://hdl.handle.net/11343/344552Test |
| الإتاحة: | https://doi.org/10.5694/mja2.52199Test http://hdl.handle.net/11343/344552Test |
| حقوق: | CC BY ; https://creativecommons.org/licenses/by/4.0Test |
| رقم الانضمام: | edsbas.4A6CB2F9 |
| قاعدة البيانات: | BASE |
| تدمد: | 0025729X 13265377 |
|---|